ENTX ENTX
Company Profile ↓Company Overview
ENTX (ENTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 11.2.
Recent Developments
- Dec 2025 Revenue of $42.00K (-76.8% YoY); net profit $-11.44M.
- Trailing 12 Months Year-on-year growth — revenue -76.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -35.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -35.11% |
| 1 Year: | -76.80% |
Stock Price Performance
| 1 Year: | +35.10% |
| 6 Months: | +128.46% |
| 3 Months: | +142.24% |
| 1 Month: | +69.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross3d ago
- RSI (14)60.71 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -35.1% CAGR over 5 years.
- Trading 28.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 109.00K | 140.00K | 68.00K | 44.00K | 8.00K | 0 | 0 | 0 | 0 | 57.00K | 42.00K | 42.00K | 0 | 0 | 0 |
| Gross Profit | 84.00K | 10.00K | 75.00K | 14.00K | 11.00K | 2.00K | 0 | 0 | 0 | - | 9.00K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.34M | -2.57M | -3.22M | -3.83M | -3.25M | -2.87M | -2.21M | -2.33M | -2.39M | -2.06M | -2.17M | -3.02M | -2.56M | -2.67M | -3.26M | -3.54M |
| Net Income | -2.30M | -2.58M | -3.21M | -3.78M | -3.19M | -3.07M | -2.19M | -2.33M | -2.38M | -2.02M | -2.15M | -3.02M | -2.57M | -2.66M | -3.20M | -3.50M |
| Diluted EPS | - | 0.10 | 0.11 | 0.13 | 0.11 | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.06 | 0.08 | 0.06 | 0.06 | 0.07 | 0.07 |
| R&D Expense | 1.12M | 1.23M | 1.77M | 1.69M | 1.39M | 1.41M | 931.00K | 1.21M | 1.37M | 735.00K | 1.09M | 1.48M | 1.12M | 1.52M | 1.64M | 2.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 365.00K | 571.00K | 134.00K | 0 | 181.00K | 42.00K |
| Gross Profit | 65.00K | 198.00K | 33.00K | 0 | 9.00K | 0 |
| Operating Income | -11.17M | -12.22M | -13.02M | -8.89M | -9.59M | -11.53M |
| Net Income | -11.22M | -12.19M | -13.07M | -8.89M | -9.54M | -11.44M |
| Diluted EPS | - | 0.47 | 0.45 | 0.31 | 0.25 | 0.25 |
| R&D Expense | 6.38M | 6.77M | 5.85M | 4.51M | 4.50M | 6.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.72M | 25.99M | 13.13M | 11.77M | 9.39M | 15.99M |
| Total Equity | 13.77M | 7.51M | 22.57M | 11.75M | 10.39M | 8.08M | 13.10M |
| Cash & Equivalents | - | 8.59M | 24.89M | 12.31M | 11.02M | 8.66M | 7.11M |
| Total Liabilities | - | 2.21M | 3.42M | 1.37M | 1.38M | 1.31M | 2.89M |
| Current Liabilities | - | 1.84M | 3.16M | 1.34M | 1.09M | 1.18M | 2.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.56M | -9.06M | -12.50M | -7.31M | -6.82M | -7.37M |
| Investing Cash Flow | -53.00K | -17.00K | -102.00K | -17.00K | -3.00K | -107.00K |
| Financing Cash Flow | 4.05M | 25.38M | 13.00K | 6.04M | 4.48M | 13.71M |
| Capital Expenditure | -53.00K | -17.00K | -47.00K | -17.00K | -3.00K | -107.00K |
| Free Cash Flow | -10.61M | -9.08M | -12.55M | -7.33M | -6.82M | -7.48M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 17.8% | 34.7% | 24.6% | - | 5.0% | 0.0% |
| Operating Margin % | -3,059.7% | -2,139.6% | -9,714.2% | - | -5,295.6% | -27,450.0% |
| Net Margin % | -3,072.9% | -2,134.3% | -9,754.5% | - | -5,271.3% | -27,235.7% |
| ROE % | -149.3% | -54.0% | -111.2% | -85.6% | -118.1% | -87.3% |
| ROCE % | -141.7% | -53.5% | -110.4% | -83.3% | -116.7% | -83.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENTX
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34…
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be part…
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide ta…
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB613…
ENTX — Frequently Asked Questions
What is the current share price of ENTX?
As of 2026-08-05 17:25 PDT, ENTX trades at $2.81 on NASDAQ/NYSE. Its 52-week range is $1.00 to $3.92.
What is the P/E ratio of ENTX?
ENTX trades at a trailing price-to-earnings (P/E) ratio of 11.24.
What is the return on equity (ROE) of ENTX?
ENTX has a return on equity (ROE) of -87.31%. Its return on capital employed (ROCE) is -83.60%.
Is ENTX a good stock to buy?
This page provides a data-driven analysis of ENTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.